Joseph Farmer, MD
Internal Medicine · Anderson, SCNPI 1760485403
Payments from drug & device makers
Across 437 payments — averaging $16.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$901
- Novartis$773
- AbbVie$740
- Lilly USA, LLC$702
- AstraZeneca$573
- Pfizer$481
- plus $3K from 33 others
What the payments were for
- Food & beverage$7,15999%
- Education$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 53 | $901 |
| Novartis | 49 | $773 |
| AbbVie(2 entities) | 48 | $740 |
| Lilly USA, LLC | 50 | $702 |
| AstraZeneca | 22 | $573 |
| Pfizer | 30 | $481 |
| Otsuka America Pharmaceutical, Inc. | 16 | $313 |
| Amgen | 22 | $295 |
| Bayer | 16 | $285 |
| GSK | 17 | $271 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 17 | $251 |
| Amarin Pharma, Inc. | 10 | $152 |
| Dexcom, Inc. | 8 | $150 |
| Sanofi-aventis U.S. LLC | 10 | $135 |
| Boehringer Ingelheim | 9 | $125 |
| Xeris Pharmaceuticals, Inc. | 6 | $112 |
| Exact Sciences | 7 | $108 |
| Abbott | 6 | $98 |
| Astellas Pharma US Inc | 4 | $85 |
| Abiomed | 3 | $66 |
| Phathom Pharmaceuticals, Inc. | 4 | $57 |
| Eisai Inc. | 2 | $53 |
| E.r. Squibb & Sons, L.L.C. | 4 | $52 |
| Intra-sana Laboratories | 3 | $52 |
| Edwards Lifesciences | 2 | $49 |
| Johnson & Johnson | 3 | $46 |
| Boston Scientific | 3 | $43 |
| Daiichi Sankyo Inc. | 2 | $39 |
| Merck | 1 | $30 |
| Esperion Therapeutics, Inc. | 1 | $25 |
| Inspire Medical Systems, Inc. | 1 | $20 |
| Hikma Pharmaceuticals USA | 1 | $19 |
| Medtronic | 1 | $18 |
| Scilex Pharmaceuticals Inc. | 1 | $18 |
| Insmed, Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,204 in reported general payments places this provider in the 90th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 539 | $286,892 |
| MounjaroTirzepatide | 149 | $169,106 |
| JardianceEmpagliflozin | 222 | $158,938 |
| OzempicSemaglutide | 106 | $107,918 |
| TrulicityDulaglutide | 97 | $101,629 |
| XareltoRivaroxaban | 127 | $87,912 |
| JanuviaSitagliptin Phosphate | 139 | $68,458 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 56 | $51,662 |
| MyrbetriqMirabegron | 177 | $46,629 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $38,580 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $36,706 |
| EntrestoSacubitril/Valsartan | 78 | $35,111 |
| FarxigaDapagliflozin Propanediol | 72 | $34,804 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 227 | $22,090 |
| Novolog FlexpenInsulin Aspart | 50 | $17,726 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Effexor Xr | $481 | $298,634550 claims |
| Lilly USA, LLCMounjaro, Trulicity | $702 | $270,735246 claims |
| Boehringer IngelheimJardiance | $125 | $158,938222 claims |
| Novo NordiskOzempic | $901 | $107,918106 claims |
| Johnson & JohnsonXarelto, Invokana | $46 | $96,396143 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $271 | $78,644116 claims |
| MerckJanuvia | $30 | $68,458139 claims |
| Astellas Pharma US IncMyrbetriq | $85 | $46,629177 claims |
| AstraZenecaFarxiga, Brilinta | $573 | $44,232116 claims |
| NovartisEntresto | $773 | $35,11178 claims |
| AbbVieNamzaric | $740 | $6,68146 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Anderson
- Carl SofleyAnderson$673K
- Anita VagnoniAnderson$21K
- Rica SantiagoMt Pleasant$10.7M
- Richard MillsMt Pleasant$5.5M
- Yvonne DavisMount Pleasant$2.4M
- David BolsterSummerville$2.3M
- Colby GrossmanSummerville$1.4M
- Amit ShahIndian Land$1.4M
- Philip NicolMurrells Inlet$782K
- Carl MitchellColumbia$564K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.